Sign in
Not yet recruitingPhase 4

Comparing treatments for sleep apnea in older people carrying extra weight

Compares treatments for obstructive sleep apnea in heavier older people.

Key facts

Who runs it
Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre
Where
Spain3 sites in 1 countryChoose a country to see its sites
Registry title
TheRapeutic StrAtegies for Obstructive SleeP Apnea in Older Adults with OverweigHt or Obesity: A RandomizEd Clinical TriaL (RAPHAEL study)
Status
Not yet recruiting
Phase
Phase 4
People taking part
345 people, planned
Started
2 Mar 2026
Expected to end
2 Mar 2028
Type of study
Interventional
Record updated
30 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 65 or older with moderate to severe obstructive sleep apnea (breathing stops during sleep) and overweight or obesity.

Age
65 years or older
Sex
All sexes
Disease stage
Moderate to severe obstructive sleep apnea, with an apnea-hypopnea index (AHI) of 15 events/h or more on a home sleep test. Active treatment must be needed. Body mass index (BMI) must be 27 kg/m² or more.
Earlier treatment
People in a weight-loss program cannot join.

Main reasons for not taking part

  • Another sleep disorder, known or suspected, or more than 50% central apneas or Cheyne–Stokes breathing
  • Very strong daytime sleepiness (Epworth Sleepiness Scale 18 or more)
  • Type 1 or type 2 diabetes
  • Severe long-term illness, such as cancer, kidney failure, severe COPD or chronic depression
  • The referring doctor says CPAP (a breathing machine used at night) is a must

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age ≥65 years
  • Diagnosis of moderate-to-severe OSA (apnea-hypopnea index [AHI] ≥15 events/h), determined by a home-based sleep apnea test, with clinical indication for active treatment according to the International Consensus Document on OSA (PMID: 33875282)
  • Overweight or obesity (body mass index [BMI] ≥27 kg/m²), consistent with recommendations for semaglutide use in individuals with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities

Who cannot take part

  • Presence or suspicion of another sleep disorder
  • Type 1 or type 2 diabetes
  • Severe chronic illness (e.g., neoplasia, renal failure, severe COPD, chronic depression)
  • >50% central apneas or Cheyne–Stokes respiration
  • Excessive daytime sleepiness (Epworth Sleepiness Scale ≥18)
  • Participation in a weight-loss program
  • Inability to adhere to interventions or assessments
  • Social or geographic limitations affecting adherence
  • Any clinical indication for which continuous positive airway pressure (CPAP) is deemed mandatory by the referring physician

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary outcome will be the change in OSA severity from baseline to the 6-month follow-up.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
TheRapeutic StrAtegies for Obstructive SleeP Apnea in Older Adults with OverweigHt or Obesity: A RandomizEd Clinical TriaL (RAPHAEL study)
Plain-language title
Comparing treatments for sleep apnea in older people carrying extra weightGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
30 March 2026